Themis Medicare Limited (NSE: THEMISMED) submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, to the National Stock Exchange on August 13, 2026, marking the company's first quarterly disclosure for the financial year 2026-27.
Dividend History and Trend
While the Q1 FY27 results announcement does not include a new dividend declaration, the company's dividend track record reveals a pronounced and sustained compression in payouts over the past several years. The board recommended a final dividend of ₹0.50 per equity share in May 2025 for FY25, identical to the ₹0.50 per share declared in May 2024 for FY24. This marks at least two consecutive years of flat payouts at the minimum level.
The contrast with earlier years is sharp. In May 2021, the board had recommended a final dividend of ₹4.30 per equity share, representing a payout 8.6 times higher than the current level. Going further back, the company declared a dividend of ₹3.00 per equity share (30% on face value) in May 2011, and a 20% dividend in June 2007. The long-term trajectory reflects a significant reduction in shareholder cash returns despite the company continuing to operate and report quarterly results.
Dividend Yield Context
With trade and quote data unavailable at the time of filing, a precise real-time dividend yield calculation is not possible. However, given that the last declared final dividend stands at ₹0.50 per equity share, investors can compute yield by dividing ₹0.50 by the prevailing market price. At any price above ₹100, the dividend yield falls below 0.5%, which is materially lower than typical pharmaceutical sector peers that maintain more consistent payout ratios. The sustained ₹0.50 payout over FY24 and FY25 suggests the board is prioritising capital retention over distribution.
Company Background
Themis Medicare Limited is a pharmaceutical company listed on NSE with ISIN INE083B01016. The company files both standalone and consolidated financial results, indicating the presence of subsidiary operations. Its filings are governed under SEBI's Listing Obligations and Disclosure Requirements regulations, and the August 13 announcement confirms compliance with quarterly result submission timelines for the April-June 2026 period.
What the Results Filing Means for Investors
- The submission of Q1 FY27 results initiates the earnings review cycle for the new financial year, with detailed revenue, EBITDA, and net profit figures now available for investor scrutiny.
- The flat ₹0.50 dividend maintained across FY24 and FY25 indicates the company has not increased shareholder returns despite any operational performance in those years, a factor relevant to income-oriented investors.
- The sharp decline from ₹4.30 per share in FY21 to ₹0.50 per share in FY24 and FY25 represents an 88% reduction in dividend per share over four years, warranting attention to the company's free cash flow generation and capital allocation strategy.
- Investors should examine the Q1 FY27 results for revenue growth, margin trajectory, and any commentary on future dividend policy before drawing conclusions on shareholder value creation.
With no current trade data or PE ratio available from the exchange at the time of this report, a full valuation comparison against the BSE Healthcare sector PE cannot be completed. Investors are advised to review the detailed financial statements now available on the NSE platform for a comprehensive assessment of Themis Medicare's Q1 FY27 performance.